Mothers of children with congenital heart disease (CHD) experience high parenting stress that affects both mothers and children.
 
  The purpose was to examine the relationship between coping self-efficacy and parenting stress in mothers of children with CHD and to identify the factors related to parenting stress.
 
  Data were collected using a self-reporting questionnaire from 100 mothers whose children, aged 0 to 12, had been diagnosed with CHD. The Coping Self-Efficacy scale was used to measure coping self-efficacy, and Pediatric Inventory for Parents was used to measure the parenting stress. Multiple linear regression analysis was conducted to investigate the factors related to parenting stress.
 
  Higher parenting stress was related to lower coping self-efficacy to obtain social support and having any other children.
 
  Interventions that consider factors related to parenting stress and to enhance coping self-efficacy is required. Effective practice could be delivered by paying more attention to mothers with less supporters and those who have other dependent children.
 Interventions that consider factors related to parenting stress and to enhance coping self-efficacy is required.  https://www.selleckchem.com/products/tph104m.html  Effective practice could be delivered by paying more attention to mothers with less supporters and those who have other dependent children.
  Despite the efficacy of adaptive servo-ventilation (ASV) in suppressing central sleep apnea (CSA), its impact on long-term outcomes is debatable. We aim to identify subjects with specific features who might benefit from ASV therapy.
 
  Randomized clinical trials and comparative observational studies investigating the effects of ASV on cardiovascular (CV) and all-cause mortality and major adverse cardiovascular events (MACEs) in CSA patients were searched from PubMed, EMBASE, Cochrane library and Web of Science. Eligible studies were identified with relative risks (RR) of death and MACEs compared between patients treated by ASV and usual care.
 
  A total of eight studies (three randomized controlled trials and five observational studies) including 2208 participants were selected for analysis. All-cause and CV mortality were not significantly reduced by ASV. Patients with nadir nocturnal saturation ≤ 80% (mean value) had lower risk of MACEs by ASV treatment compared with by usual care (RR, 0.18; p<0.001). Patients with severe heart failure (HF), defined as left ventricular ejection fraction (LVEF) ≤ 33% (mean value), or HF of New York Heart Association (NYHA) classification of III/IV, did not have reduced risk of MACEs post ASV therapy. However, subjects with LVEF>33% (RR, 0.35; p<0.001) or NYHA Ⅰ/Ⅱ (RR, 0.35; p<0.001) had significantly lower risk of MACEs by using ASV than by usual care.
 
  Although ASV appears to not reduce CV and all-cause death for HF patients with extremely low LVEF, those with profound CSA associated hypoxemia or less severe HF still benefit from ASV therapy.
 Although ASV appears to not reduce CV and all-cause death for HF patients with extremely low LVEF, those with profound CSA associated hypoxemia or less severe HF still benefit from ASV therapy.
  Oxidized LDL receptor 1 (OLR1) encodes LOX-1, LOXIN, and OLR1D4 transcript variants. Up-regulation of LOX-1 and down-regulation of LOXIN have an essential role in causing coronary artery disease (CAD). Discovery of risk single nucleotide polymorphisms (SNPs) in OLR1 gene is clinically important as these polymorphisms could be candidate biomarkers of CAD.
 
  The purpose of this study is quantitative evidence synthesis on how OLR1 polymorphisms in the haplotype block impact the risk of CAD.
 
  First, a systematic keyword-based search in PubMed, Web of Science, and Scopus was conducted. After data extraction, pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for OLR1 polymorphisms and CAD. Twelve case-control studies, including 6,238 cases and 15,773 controls, were concluded in the meta-analysis.
 
  Our findings demonstrate significant association of OLR1 polymorphisms in the haplotype block with CAD risk in all genetic models (allelic model OR=1.19, 95%CI=1.06-1.34; additive model OR=1.54, 95%CI=1.16-2.05; recessive model OR=1.26, 95%CI=1.04-1.53; dominant model OR=1.28, 95%CI=1.09-1.51). Subgroup analysis based on the type of polymorphism revealed that rs1050283 (3'UTR*188 C>T) and rs3736235 (IVS4-14 A>G) are more significantly associated with the risk of CAD compared to other polymorphisms in the haplotype block.
 
  We found a significant association between OLR1 polymorphisms in the haplotype block, especially rs1050283 and rs3736235, with CAD. We also suggest that precise determination of disease association with polymorphisms in a haplotype requires investigation of all SNPs rather than a single SNP in that specific haplotype.
 We found a significant association between OLR1 polymorphisms in the haplotype block, especially rs1050283 and rs3736235, with CAD. We also suggest that precise determination of disease association with polymorphisms in a haplotype requires investigation of all SNPs rather than a single SNP in that specific haplotype.
  Coronavirus disease 2019 (COVID-19) has become a global health threat, and thus, an early and effective set of predictors is needed to manage the course of the disease.
 
  We aim to determine the effect of SARS-CoV-2 on lipid profile and to evaluate whether the atherogenic index of plasma (AIP) could be used to predict in-hospital mortality in COVID-19 patients.
 
  In this retrospective chart review study, a total of 139 confirmed COVID-19 patients, whose diagnoses are confirmed by PCR and computerized tomography results, are enrolled. The study population is divided into two groups the deceased patient group and the survivor group. For each patient, fasting total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and the triglyceride values are obtained from the laboratory tests required at the admission to hospital. Finally, the AIP is calculated as the base 10 logarithm of the triglyceride to HDL-C ratio. Distributional normality of the data is checked and depending on the normality of the data, either T test or Mann Whithey U test is employed to compare the two aforementioned study groups.